NHP Stock Forecast & Price Target

National Healthcare is attractive because it is executing a clear shift from lower-growth OMF assets toward a SHOP-heavy portfolio, where same-store NOI growth is materially stronger and supported by favorable senior housing supply-demand fundamentals. The 2Q26 report validated that strategy, with normalized FAD per share of $0.18 ahead of expectations, same-store SHOP cash NOI up 20.1% year over year, occupancy at 84.1%, and margins expanding 230 bps, while 2026 SHOP same-store cash NOI guidance rose to 15.0%-18.0%. Fundamentally, the balance sheet has improved sharply after the IPO and refinancing, with net debt to annualized adjusted EBITDA at 4.6x, about $1B of liquidity, and increasing capital recycling from MOB sales into higher-yielding SHOP acquisitions, positioning earnings to accelerate further.

National Healthcare is viewed negatively because its portfolio is still transitioning from lower-growth OMF assets to SHOP, a shift that depends on selling $528mm of OMF properties and funding about $400mm of SHOP acquisitions in 2026 with no execution missteps. The business also faces structural downside from SHOP/RIDEA operating risk, higher leverage, and limited scale, while same-store OMF cash NOI already declined 40 bps yr/yr to $20.2mm and OMF growth has lagged SHOP at 7.6% versus 24%. Further pressure comes from likely external capital needs, a 180-day lock-up on roughly 40% of the share base expiring on October 19, 2026, and regulatory and reimbursement risk that could hit tenant cash flows and dividend support.